CinRx Pharma
CinRx Pharma is a Cincinnati-based hub-and-spoke biotech founded in 2015 that creates asset-focused portfolio companies ("CinCos") to advance therapeutic candidates in gastroparesis, obesity, and IBS-D through clinical development. The model relies on centralized infrastructure, a Medpace partnership, and eventual licensing or acquisition by major pharmaceutical partners.
- Company typePrivate
- Founded2015
- HeadquartersCincinnati, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CinRx Pharma does
CinRx Pharma is a privately held, hub-and-spoke clinical-stage biotechnology company founded in 2015 and headquartered in Cincinnati, Ohio. The company creates and operates asset-focused portfolio subsidiaries — branded as "CinCos" — that advance therapeutic candidates through clinical development across cardiovascular, metabolic, and gastrointestinal indications. Its active portfolio includes CinDome Pharma (deudomperidone/CIN-102, a deuterated domperidone formulation in Phase 2 for diabetic and idiopathic gastroparesis, addressing an estimated 12-16 million U.S. patients with no FDA-approved long-term treatment), CinFina Pharma (CIN-110 PYY analog and CIN-109 GDF-15 molecule in-licensed from Janssen for obesity), CinPhloro Pharma (CIN-103 pulsatile-release phloroglucinol in Phase 2 for IBS-D), and CinPressa Pharma (a pre-clinical asset advancing to the clinic). CinCor Pharma (baxdrostat/CIN-107, an aldosterone synthase inhibitor licensed from Roche) was previously incubated and exited via $194M IPO in 2022 and subsequent $1.8B acquisition by AstraZeneca in January 2023.
CinRx's core operating technology is its hub-and-spoke platform: a centralized execution engine of cross-functional experts in CMC, toxicology, clinical pharmacology, clinical operations, quality, and finance supports each CinCo from a shared infrastructure, while a strategic, deeply integrated partnership with Medpace provides embedded global clinical trial execution and regulatory expertise. The model is designed for capital efficiency — frictionless redeployment of resources to assets at inflection points — and has now been validated by both clinical milestones (two completed Phase 2 enrollments in 2025-2026) and a marquee exit (CinCor/AstraZeneca).
CinRx's business model is to generate value by advancing therapeutic candidates to clinical and regulatory milestones, then either licensing them to or transacting them with larger pharmaceutical companies. The company funds its operations through equity financings — $176M raised to date, with a $73M round in May 2024 and subsequent CinDome Series B extensions in 2024-2025 — and monetizes through milestone-driven capital deployment, licensing royalties, and acquisition exits. The company employs 11-50 people and serves patients with high unmet medical needs in gastroparesis, obesity, IBS-D, and (historically) hypertension/cardiorenal disease via its eventual pharmaceutical partners.
CinRx Pharma firmographics
Firmographics- Name
- CinRx Pharma
- Legal name
- CinRx Pharma, Inc.
- Website
- http://www.cinrx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CinRx Pharma is a Cincinnati-based hub-and-spoke biotech founded in 2015 that creates asset-focused portfolio companies ("CinCos") to advance therapeutic candidates in gastroparesis, obesity, and IBS-D through clinical development. The model relies on centralized infrastructure, a Medpace partnership, and eventual licensing or acquisition by major pharmaceutical partners.
- Ownership category
- akta.pro rank
CinRx Pharma industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Medical and Diagnostic Laboratories (6215)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)
Keywords
Where CinRx Pharma is headquartered
LocationHeadquarters
- HQ city
- Cincinnati
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
CinRx Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Licensing: CinRx Pharma generates value by advancing therapeutic candidates through clinical development and either commercializing them directly or licensing to larger pharmaceutical companies. The company creates asset-focused portfolio companies (CinCos) that are designed for eventual acquisition or partnership with major pharma companies, as demonstrated by CinCor Pharma's $1.8 billion acquisition by AstraZeneca.
- Portfolio Company Financing: CinRx provides initial financing and milestone-driven capital deployment to portfolio companies, with returns generated through successful clinical development outcomes and subsequent value creation for potential acquisition or IPO.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
CinRx Pharma product offering
Product offeringCore offering
CinRx Pharma operates a hub-and-spoke biotech platform that creates asset-focused portfolio companies ("CinCos") to advance clinical-stage therapeutic candidates through development. The company provides centralized strategic capital, cross-functional expertise, and a strategic partnership with Medpace for global clinical trial execution. Current CinCos include CinDome Pharma (deudomperidone/CIN-102 for gastroparesis), CinFina Pharma (obesity pipeline including CIN-110 and CIN-109), CinPhloro Pharma (CIN-103 for IBS-D), and CinPressa Pharma (pre-clinical asset), with CinCor Pharma (baxdrostat) having been acquired by AstraZeneca.
Product overview
CinRx Pharma is a hub-and-spoke, multi-asset clinical development organization advancing a diverse portfolio of high-impact medicines through asset-focused subsidiary companies called 'CinCos'. The company provides centralized infrastructure including financing, cross-functional expertise, and a strategic partnership with Medpace for clinical trial execution. The portfolio includes multiple clinical-stage therapeutic candidates across therapeutic areas of high unmet medical need: gastrointestinal (deudomperidone/CIN-102 for gastroparesis, CIN-103 for IBS-D), metabolic (CIN-110 and CIN-109 for obesity), and formerly cardiovascular (baxdrostat/CIN-107, acquired by AstraZeneca).
Differentiator
Problem solved
Functional benefit
Brands
- CinCos: Asset-focused portfolio companies operated by CinRx Pharma under its hub-and-spoke model, including CinDome Pharma, CinPressa Pharma, CinCor Pharma (acquired), CinFina Pharma, and CinPhloro Pharma.
Products and services
- Deudomperidone (CIN-102) A novel deuterated formulation of domperidone (a D2/D3 dopamine agonist) engineered to blunt peak plasma concentration (Cmax) and extend half-life versus traditional domperidone. Designed as a safe, chronic therapy for gastroparesis with significantly reduced QT prolongation liability, addressing an estimated 12–16 million U.S. patients with no current FDA-approved long-term treatment. In Phase 2 development at CinDome Pharma for both diabetic gastroparesis (envision3D) and idiopathic gastroparesis (envisionGI).
- CIN-110 A PYY (Peptide YY) analog being developed by CinFina Pharma for the treatment of obesity. Licensed from Janssen Pharmaceuticals as part of a four-asset obesity pipeline. Designed to provide a safe, tolerable, and durable option for obesity treatment distinct from GLP-1 mechanisms.
- CIN-109 A novel GDF-15 molecule being developed by CinFina Pharma for obesity treatment with focus on body composition and lean body mass preservation, evaluated both as monotherapy and in combination with semaglutide. Licensed from Janssen Pharmaceuticals.
- CIN-103 A pulsatile-release formulation of phloroglucinol modified for sustained exposure and less frequent dosing, being developed by CinPhloro Pharma for the long-term management of irritable bowel syndrome with diarrhea (IBS-D). Currently in Phase 2 enviva study.
Quantifiable outcome
- CinCor Pharma acquired by AstraZeneca for $1.8 billion (including $1.3 billion upfront and $500 million in biobucks)
- +3 more outcomes
Companies that use CinRx Pharma
Customer profileSegments5 records
Ideal customer profiles3 records
CinRx Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CinRx Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- AstraZenecaflagshipAstraZeneca acquired CinCor Pharma (a CinRx portfolio company) in early 2023 in a deal worth $1.3 billion upfront plus $500 million in biobucks. CinCor was created to advance baxdrostat (CIN-107), a highly selective oral small molecule inhibitor of aldosterone synthase for treatment of hypertension and other cardiorenal conditions. CinRx led clinical design and execution, responsible for Series A and B financings and IPO funding.
- MedpacecoreStrategic, deeply integrated partnership with Medpace provides immediate, seamless access to global trial execution capabilities and global regulatory know-how. This partnership serves as embedded clinical infrastructure, turning typical operational hurdles into a competitive speed advantage for CinRx's portfolio companies.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
CinRx Pharma competitors and assessment
Company assessmentDirect peers
- Roivant Sciences: Roivant operates the most prominent hub-and-spoke biotech platform, creating multiple 'Vants' focused on individual therapeutic assets with shared infrastructure, mirroring CinRx's CinCo model. Both platforms spin out asset-focused subsidiaries, advance them through clinical development, and pursue strategic exits to large pharma, making the operating philosophy, capital deployment, and exit economics directly comparable.
- BridgeBio Pharma: BridgeBio runs a multi-asset genetic disease and specialty pharma platform with affiliated subsidiaries developing individual programs, sharing CinRx's model of centralized expertise supporting multiple asset-focused entities. Both companies pursue a 'many shots on goal' strategy with the goal of licensing or partnering successful assets, and have raised substantial private and public capital to support parallel clinical programs.
- PureTech Health: PureTech is a clinical-stage platform company that founded and develops multiple therapeutic programs through Founded Entities, paralleling CinRx's CinCo creation function. Both companies leverage centralized R&D and operational infrastructure to advance multiple clinical-stage assets with the intent of partnerships, spinouts, or exits.
- Ardelyx: Ardelyx is a gastroenterology-focused specialty pharmaceutical company developing treatments for GI disorders, directly comparable to CinRx's CinDome franchise targeting gastroparesis. Both companies address underserved GI conditions with novel mechanisms and have pursued strategic partnerships to commercialize their therapies.
- Ventyx Biosciences: Ventyx is a clinical-stage biotech developing novel therapies for inflammatory and gastrointestinal diseases, sharing CinRx's therapeutic focus on GI indications and clinical-stage development profile. Both companies are advancing multiple assets through Phase 2 trials in GI indications with similar capital structures and partnership potential.
Emerging players
- Cerevel Therapeutics: Cerevel was a clinical-stage biotech spun out of Pfizer that advanced multiple CNS programs in parallel, similar to CinRx's portfolio approach, and was ultimately acquired by AbbVie for $8.7B. The parallel-platform model with centralized clinical execution and a major pharma exit precedent makes it highly relevant for valuing CinRx's CinCo exit trajectory.
- Anthos Therapeutics: Anthos is a Blackstone-backed clinical-stage biotech developing novel cardiovascular therapeutics, sharing CinRx's parent-company-supports-portfolio-companies structure and capital efficiency focus. Both companies leverage deep-pocketed backing and centralized expertise to advance multiple clinical assets with the intent of out-licensing or acquisition by large pharma.
- Structure Therapeutics: Structure Therapeutics is a clinical-stage biotech developing oral small molecule therapies for obesity and cardiometabolic diseases, sharing CinRx's CinFina therapeutic area and small-molecule modality focus. Both companies are advancing differentiated mechanisms (non-injectable, novel targets) into competitive therapeutic areas with substantial M&A interest from large pharma.
Broad incumbents
- Eli Lilly: Eli Lilly is a large pharmaceutical incumbent with an active gastroenterology and metabolic disease franchise (including Zepbound/Mounjaro in obesity and several GI pipeline assets), making it both a potential acquirer of CinRx CinCos and a benchmark for commercial-stage valuation. Its scale in obesity and GI makes it a relevant comparable for assessing CinRx's eventual exit potential.
- AstraZeneca: AstraZeneca is the strategic acquirer of CinCor Pharma (CinRx portfolio company) for $1.8B and represents the validated exit counterparty for CinRx's hub-and-spoke model. AZ's active business development in cardiovascular, gastrointestinal, and rare disease makes it the most directly relevant large-pharma comparable for assessing future CinCo exit economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CinRx Pharma social profiles
Digital presenceCinRx Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
CinRx Pharma leadership team
Management profileNumber of profiles
Profiles23 records
CinRx Pharma subsidiaries and ownership
Company hierarchySubsidiaries5 records
CinRx Pharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CinRx Pharma M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CinRx Pharma
What does CinRx Pharma do?
CinRx Pharma operates a hub-and-spoke biotech platform that creates asset-focused portfolio companies ("CinCos") to advance clinical-stage therapeutic candidates through development. The company provides centralized strategic capital, cross-functional expertise, and a strategic partnership with Medpace for global clinical trial execution. Current CinCos include CinDome Pharma (deudomperidone/CIN-102 for gastroparesis), CinFina Pharma (obesity pipeline including CIN-110 and CIN-109), CinPhloro Pharma (CIN-103 for IBS-D), and CinPressa Pharma (pre-clinical asset), with CinCor Pharma (baxdrostat) having been acquired by AstraZeneca.
Is CinRx Pharma a public or private company?
CinRx Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was CinRx Pharma founded?
CinRx Pharma was founded in 2015. It employs 11 to 50 people.
Where is CinRx Pharma based?
CinRx Pharma is headquartered in Cincinnati, United States, in the North America region.
How does CinRx Pharma make money?
Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are portfolio Company Financing.
Who are CinRx Pharma's main competitors?
Direct peers on record are Roivant Sciences, BridgeBio Pharma, PureTech Health, Ardelyx and Ventyx Biosciences. Emerging players are Cerevel Therapeutics, Anthos Therapeutics and Structure Therapeutics. Broad incumbents are Eli Lilly and AstraZeneca.
Does CinRx Pharma have an API?
No public API is recorded for CinRx Pharma.
What industry is CinRx Pharma in?
CinRx Pharma's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 6215 and its SIC code is 2834.